Combination Therapy in Participants With Active Psoriatic Arthritis Using Subcutaneous Guselkumab and Golimumab: Week 24 Results From the Phase 2a, Multicenter, Randomized, Double-Blind, Proof-of-Conc
5 hours ago
- #Clinical Trial
- #Psoriatic Arthritis
- #Combination Therapy
- The study evaluated guselkumab and golimumab combination therapy versus guselkumab monotherapy in TNFi-IR PsA patients.
- Primary endpoint (Week 24 MDA achievement) was not met (29% combination vs. 22% monotherapy, P=0.557).
- Secondary endpoints showed higher ACR50 response with combination therapy (44% vs. 22%, nominal P=0.034).
- Patients with CRP ≥0.3mg/dL had better MDA (32% vs. 5%) and ACR50 (55% vs. 14%) responses with combination therapy.
- Combination therapy also improved ACR20/70 responses and physical function compared to monotherapy.
- No new safety signals or opportunistic infections were reported through Week 36.
- Results suggest potential benefits for TNFi-IR PsA patients with elevated CRP, warranting further investigation.